LOXL2 Inhibition: A New Frontier in Treating LMNA-Related Dilated Cardiomyopathy

MedXY Editorial Team•Mar 17, 2026•Cardiology

Simtuzumab, a monoclonal antibody targeting LOXL2, significantly attenuates myocardial fibrosis and prevents the decline of left ventricular function in LMNA-associated dilated cardiomyopathy models.
LMNA mutations (p.His222Pro) lead to structural nuclear abnormalities and disrupted chromosome spatial organization, which triggers the upregulation of pro-fibrotic genes, specifically LOXL2.
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with LMNA mutations exhibit diastolic calcium overload and reduced contractile force in 3D engineered heart tissues.
Targeting the extracellular matrix (ECM) remodeling pathway via LOXL2 inhibition offers a disease-modifying strategy for patients with aggressive laminopathies.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Simtuzumab, a monoclonal antibody targeting LOXL2, significantly attenuates myocardial fibrosis and prevents the decline of left ventricular function in LMNA-associated dilated cardiomyopathy models.
LMNA mutations (p.His222Pro) lead to structural nuclear abnormalities and disrupted chromosome spatial organization, which triggers the upregulation of pro-fibrotic genes, specifically LOXL2.
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with LMNA mutations exhibit diastolic calcium overload and reduced contractile force in 3D engineered heart tissues.
Targeting the extracellular matrix (ECM) remodeling pathway via LOXL2 inhibition offers a disease-modifying strategy for patients with aggressive laminopathies.